Screener
Taysha Gene Therapies, Inc. TSHA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | 1,289 | 923 |
| Accrued expenses and other liabilities | (5,149) | (2,125) |
| Deferred revenue | — | (2,302) |
| Net cash used in operating activities | (40,878) | (22,020) |
| Cash flows from investing activities | ||
| Purchase of research and development license | (3,000) | — |
| Purchase of property, plant and equipment | (24) | (378) |
| Other | — | 7 |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s operating cash flow?
- Taysha Gene Therapies, Inc. (TSHA) reported operating cash flow of -$40.88M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s operating cash flow changed year-over-year?
- Taysha Gene Therapies, Inc.'s operating cash flow decreased by 85.6% year-over-year, from -$22.02M to -$40.88M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s operating cash flow?
- Over 3 years (2021 to 2025), Taysha Gene Therapies, Inc.'s operating cash flow has grown at a -7.3% compound annual growth rate (CAGR), from -$117.04M to -$93.09M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Taysha Gene Therapies, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude